|
Video: What is a Stock Split?
|
|
Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on the development of products that address unmet needs in Central Nervous System disorders and other disorders. Co.'s primary programs are SLS-002 for the potential treatment of Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia. SLS-005 for the potential treatment of Sanfilippo Syndrome requires additional natural history data, which is being considered. Co. is also developing several preclinical programs, including SLS-004 and SLS-007, for the potential treatment of Parkinson's Disease. According to our SEEL split history records, Seelos Therapeutics has had 2 splits. | |
|
Seelos Therapeutics (SEEL) has 2 splits in our SEEL split history database. The first split for SEEL took place on January 24, 2019. This was a 1 for 30 reverse split, meaning for each 30 shares of SEEL owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split. SEEL's second split took place on November 28, 2023. This was a 1 for 30 reverse split, meaning for each 30 shares of SEEL owned pre-split, the shareholder now owned 1 share. For example, a 33.3333333333333 share position pre-split, became a 1.11111111111111 share position following the split.
When a company such as Seelos Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the SEEL split history from start to finish, an original position size of 1000 shares would have turned into 1.11111111111111 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Seelos Therapeutics shares, starting with a $10,000 purchase of SEEL, presented on a split-history-adjusted basis factoring in the complete SEEL split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/02/2014 |
|
End date: |
04/30/2024 |
|
Start price/share: |
$1,926.00 |
|
End price/share: |
$0.28 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.99% |
|
Average Annual Total Return: |
-58.66% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1.45 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
01/24/2019 | 1 for 30 | 11/28/2023 | 1 for 30 |
|
|